# A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

> **NCT04603989** · PHASE1 · COMPLETED · sponsor: **Guangzhou Henovcom Bioscience Co. Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** HNC042 for Injection
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT04603989
- **Lead sponsor:** Guangzhou Henovcom Bioscience Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-01
- **Primary completion:** 2020-11-13
- **Final completion:** 2020-11-13
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04603989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04603989, "A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04603989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*